Prevalence and long-term effects of occult hepatitis B virus infection in HIV-infected women

Clinical Infectious Diseases

Volumn 45, Issue 6, 2007, Pages 736-740

  Tsui, Judith I ^a,b   French, Audrey L ^d   Seaberg, Eric C ^e   Augenbraun, Michael ^f   Nowicki, Marek ^c   Peters, Marion ^a   Tien, Phyllis C ^a,b,g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d Jr Hospital of Cook County   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f SUNY DOWNSTATE MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; DIDANOSINE; HEPATITIS B CORE ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; SAQUINAVIR; STAVUDINE; TENOFOVIR; VIRUS DNA; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; ENZYME IMMUNOASSAY; FEMALE; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; SEROLOGY; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS HEPATITIS;

ADULT; CD4 LYMPHOCYTE COUNT; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; HIV INFECTIONS; HUMANS; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; TIME FACTORS; UNITED STATES;

EID: 34548490925     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/520989     Document Type: Article

References (11)

1. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002;2:479-86.
2. Hofer M, Joller-Jemelka HI, Grob PJ, Luthy R, Opravil M. Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study. Eur J Clin Microbiol Infect Dis 1998; 17:6-13.
3. Neau D, Winnock M, Galperine T, et al. Isolated antibodies against the core antigen of hepatitis B virus in HIV-infected patients. HIV Med 2004; 5:171-3.
4. Bacon MC, von Wyl V, Alden C, et al. The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol 2005; 12:1013-9.
5. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology 1998; 9:117-25.
6. Neau D, Winnock M, Jouvencel AC, et al. Occult hepatitis B virus infection in HIV-infected patients with isolated antibodies to hepatitis B core antigen: Aquitaine cohort, 2002-2003. Clin Infect Dis 2005; 40:750-3.
7. Nunez M, Rios P, Perez-Olmeda M, Soriano V. Lack of 'occult' hepatitis B virus infection in HIV-infected patients. AIDS 2002; 16:2099-101.
8. Shire NJ, Rouster SD, Rajicic N, Sherman KE. Occult hepatitis B in HIV-infected patients. J Acquir Immune Defic Syndr 2004; 36:869-75.
9. Mphahlele MJ, Lukhwareni A, Burnett RJ, Moropeng LM, Ngobeni JM. High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. J Clin Virol 2006; 35:14-20.
10. Peters MG, Andersen J, Lynch P, et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006;44:1110-6.
11. Filippini P, Coppola N, Pisapia R, et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS 2006; 20:1253-60.